Literature DB >> 9268238

Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease.

J A Molina1, F J Jiménez-Jiménez, P Gomez, C Vargas, J A Navarro, M Ortí-Pareja, T Gasalla, J Benito-León, F Bermejo, J Arenas.   

Abstract

We measured the CSF levels of 21, and the plasma levels of 26, amino acids in 31 patients with Parkinson's disease (PD) and in 45 matched controls. We used an ion-exchange chromatography method. When compared to controls, PD patients had lower CSF levels of taurine, alanine, valine, leucine, isoleucine, ethanolamine, citrulline, ornithine, lysine, histidine, arginine, and alpha-aminobutyric acid. PD patients not treated with levodopa or with dopamine agonists had higher CSF tyrosine and phenylalanine levels than those not treated with these drugs and also than controls. PD patients had higher plasma levels of phosphoserine, threonine, methionine, tyrosine, sarcosine and alpha-aminoadipic acid, and lower plasma levels of valine, leucine, and tryptophan, than controls. The CSF/plasma ratio of many of these amino acids was significantly lower in PD patients than those of controls, suggesting that PD patients might have a dysfunction in the transport of neutral and basic amino acids across the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9268238     DOI: 10.1016/s0022-510x(97)00069-5

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  35 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

Review 2.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

3.  Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.

Authors:  Elena L Paley; Galina Denisova; Olga Sokolova; Natalia Posternak; Xukui Wang; Anna-Liisa Brownell
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

4.  Effect of pluronic p85 on amino acid transport in bovine brain microvessel endothelial cells.

Authors:  Xiaobin Zhang; Daria Y Alakhova; Elena V Batrakova; Shu Li; Zhihui Yang; Yili Li; Alexander V Kabanov
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-02       Impact factor: 4.147

Review 5.  The role of environmental exposures in neurodegeneration and neurodegenerative diseases.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Toxicol Sci       Date:  2011-09-13       Impact factor: 4.849

6.  A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study.

Authors:  Jacopo Troisi; Annamaria Landolfi; Carmine Vitale; Katia Longo; Autilia Cozzolino; Massimo Squillante; Maria Cristina Savanelli; Paolo Barone; Marianna Amboni
Journal:  Metabolomics       Date:  2019-06-10       Impact factor: 4.290

7.  Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease.

Authors:  Jian Ding; Jiejin Zhang; Xixi Wang; Li Zhang; Siming Jiang; Yongsheng Yuan; Junyi Li; Lin Zhu; Kezhong Zhang
Journal:  J Neural Transm (Vienna)       Date:  2016-11-22       Impact factor: 3.575

8.  Could lysine supplementation prevent Alzheimer's dementia? A novel hypothesis.

Authors:  Robert N Rubey
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-27       Impact factor: 2.570

9.  Correlations between plasma levels of amino acids and nonmotor symptoms in Parkinson's disease.

Authors:  Qing Tong; Qinrong Xu; Qiang Xia; Yongsheng Yuan; Li Zhang; Hongbin Sun; Han Shan; Kezhong Zhang
Journal:  J Neural Transm (Vienna)       Date:  2014-07-25       Impact factor: 3.575

Review 10.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.